Guess Which Network Became Totally Unglued Yesterday
You Knew Iran Was Going to Target US Forces in Iraq
Leftists Are Rioting in Los Angeles Again
Anything Bad for Iran Is Good for America and the World
De Tocqueville on Human 'Rights'
A Quick Bible Study Vol. 272: On Father’s Day, What the Bible Says...
You Started It
A Silver Lining to the Orchestrated LA Riots
This Father’s Day, President Trump Must Commit to Protecting America’s Fathers From Their...
Summer Success at the Box Office Shows Why Hollywood Should Focus on Families
Founding Father’s Day: John Adams’s Parental and Patriotic Duty
What Conservative Christians Need to Know About Israel
Delegitimizing Christianity in the Land in Which Jesus Was Born
Trump Honors 250 Years of U.S. Army Might with Patriotic Parade and Powerful...
Fetterman Breaks With the Left Again, Praises Trump’s Military Parade
Tipsheet

AstraZeneca COVID Vaccine Trial Exceeds Expectations After Controversy

AP Photo/Kirsty Wigglesworth

Could a fourth COVID vaccine be on the horizon? There's been some controversy and negative coverage of AstraZeneca's shot, developed with the University of Oxford. The European Medicines Agency approved the shot in January, but at least 16 European countries stopped distribution of the vaccine due to concerns about blood clots. About 30 recipients of the vaccine, most of whom were women under the age of 55, were reportedly diagnosed with cerebral venous sinus thrombosis.

Advertisement

But a new U.S. clinical trial of 30,000 people has produced some positive results that may put those fears to rest. The trial "confirmed the safety profile of the vaccine," reports CNBC. The vaccine proved to be 79 percent effective in preventing symptomatic COVID, and 100 percent effective in preventing hospitalization.

The trial included over 30,000 participants and showed that the vaccine had an overall efficacy of 79% in preventing symptomatic Covid-19 and was 100% effective in preventing severe disease and hospitalization.

Efficacy was consistent across age and ethnic group, with 80% efficacy in participants aged 65 years and over. The vaccine, known as AZD1222 and developed with the University of Oxford, was well-tolerated and the independent data safety monitoring board identified no safety concerns related to the vaccine. 

A group of German researchers recently issued a statement connecting the vaccine to a risk of blood clots, but the U.S. trial appeared to upend that assessment.

Advertisement

Health experts say there should now be nothing holding AstraZeneca back from getting the FDA's blessing.

“I can’t see why the regulator wouldn’t approve it,” Adam Barker, healthcare analyst at Shore Capital, wrote.

Three COVID-19 vaccines are currently FDA approved, including those produced by Pfizer-BioNTech, Moderna, and Johnson & Johnson, the last of which only requires one dose.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement